The purpose of this study is to transition patients who have been stable on Belatacept for
one year after kidney transplant from standard 4-week to an investigational 8-week belatacept
dosing schedule. The investigators hypothesize that renal function and acute rejection rates
will be non-inferior with 8-week belatacept dosing.